ClinicalTrials.gg
CompletedNCT03606057Updated Mar 3, 2020

A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)

A Phase 1 interventional study of JNJ-64565111 and Moxifloxacin in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2019, 7 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the effects on placebo-corrected change from baseline QT interval corrected for individual heart rate (QTcI) of JNJ-64565111 close to steady state on Day 26 and on electrocardiogram morphology at supratherapeutic exposures in otherwise healthy overweight/obese adults after 4 weeks of treatment with JNJ 64565111 administered subcutaneously once weekly.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 25.0 and 40.0 kilogram per square meter ( kg/m\^2), inclusive, and a body weight of not less than 80 kg
  • Blood pressure (BP) between 90 and 140 millimeter of mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic
  • If a woman, must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at screening
  • If a woman, must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study (from screening through Day 56) or until 30 days after the last dose of study drug for participants that withdraw early from the study
  • QRS interval of less than or equal to (\<=) 110 milliseconds (ms)
  • An average of triplicate 12-lead safety (ECG) recording, completed within 4 minutes total, consistent with normal cardiac conduction and function at screening, including

    1. Normal sinus rhythm (heart rate between 45 and 100 beats per minute [inclusive])
    2. corrected for heart rate according to Fridericia's formula (QTcF) interval between 350 to 450 ms (inclusive)
    3. PR interval \<= 200 ms
    4. ECG morphology consistent with healthy cardiac conduction and function

Exclusion criteria

Exclusion Criteria:

  • Taken any disallowed therapies as defined in a protocol before the planned first dose of study drug
  • abnormal values for hematology, clinical chemistry, or urinalysis at screening or at admission to the study
  • Clinically significant abnormal physical examination, vital signs, or 12 lead at screening or at admission to the study site
  • Known allergies, , or intolerance to JNJ-64565111, moxifloxacin, or its
  • or C infection
  • History of additional risk factors for torsade de pointes or the presence of a family history of Short Syndrome, Long QT Syndrome, sudden unexplained death at a young age (\<= 40 years), or sudden infant death syndrome in a first-degree relative (that is biological parent, sibling, or child)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    Treatment Group 1: JNJ-64565111+Moxifloxacin Placebo

    Participant will receive JNJ-64565111 on days 2, 9, 16, and 23 and moxifloxacin-matching placebo on days 1 and 27.

    Drug: JNJ-64565111 · Drug: Moxifloxacin-matching Placebo

  • Active comparator
    Treatment Group 2: JNJ-64565111 Matching Placebo+Moxifloxacin

    Participant will receive JNJ-64565111-matching placebo on days 2, 9, 16, and 23. Participants will also receive moxifloxacin on day 1 and moxifloxacin-matching placebo on day 27 (sequence 2a) or moxifloxacin-matching placebo on day 1 and moxifloxacin on day 27 (sequence 2b) in a nested crossover manner.

    Drug: Moxifloxacin · Drug: JNJ-64565111-matching Placebo · Drug: Moxifloxacin-matching Placebo

Interventions

  • Participants will receive JNJ-64565111, subcutaneously on days 2, 9, 16, and 23.

  • Participants will receive moxifloxacin capsule on days 1 or 27 in a nested crossover manner.

  • DrugJNJ-64565111-matching Placebo

    Participants will receive JNJ-64565111-matching Placebo vehicle solution subcutaneously on days 2, 9, 16, and 23.

  • DrugMoxifloxacin-matching Placebo

    Participants will receive moxifloxacin-matching placebo capsule on days 1 and 27 in treatment group 1 and on day 1 or 27 in treatment group 2.

06

What researchers measure

Primary outcomes

  1. Placebo-Corrected Change from Baseline in QT Interval Corrected for Individual Heart Rate (QTcI) on Day 26 Time-Matched Time Points

    Placebo-corrected change from baseline in QT interval corrected for individual heart rate (QTcI) on day 26 time-matched time points will be determined. The mean change from baseline in QTcI for participants who receive placebo will be subtracted from the mean change from baseline in QTcI for participants on JNJ-64565111 at the same time point to generate placebo-corrected change from baseline in QTcI, which will be presented.

    Time frame: Baseline and Day 26

  2. Change from Time-Matched Baseline in QTc Interval

    The QT interval corrected for heart rate (QTc interval) using Fridericia method will be measured by electrocardiograms (ECG).

    Time frame: Up to Day 27

  3. Change from Time-Matched Baseline in Heart Rate (HR)

    The HR will be measured by ECG.

    Time frame: Up to Day 27

  4. Change from Time-Matched Baseline in QRS Interval

    The QRS Intervals will be measured by ECG.

    Time frame: Up to Day 27

  5. Change from Time-Matched Baseline in PR Interval

    The PR intervals will be measured by ECG.

    Time frame: Up to Day 27

Secondary outcomes

  1. Cardiac Repolarization as Determined by Mean Change from Time-Matched Baseline in QT Interval Corrected for Individual HR (QTcI) on Day 5

    Mean change from time-matched baseline in QT interval corrected for individual HR (QTcI) on day 5 to determine the effect of JNJ-64565111 on cardiac repolarization.

    Time frame: Baseline and Day 5

  2. Cardiac Repolarization as Determined by Mean Change from Time-Matched Baseline in QT Interval Corrected For HR Using Fridericia's Formula (QTcF) on Day 5 and Day 26

    Mean change from time-matched baseline in QT interval corrected for HR using Fridericia's formula (QTcF) will be assessed on day 5 and day 26 to determine the effect of JNJ-64565111 on cardiac repolarization.

    Time frame: Baseline, Day 5 and Day 26

  3. Maximum Observed Serum Concentration (Cmax)

    Cmax is defined as the maximum observed serum analyte concentration.

    Time frame: Days 1, 5, 26 and 27

  4. Time to Reach Maximum Observed Serum Concentration (Tmax)

    Tmax is defined as actual sampling time to reach maximum observed serum analyte concentration.

    Time frame: Days 1, 5, 26 and 27

  5. Average Serum Analyte Concentration (Cavg)

    Cavg is defined as average serum analyte concentration.

    Time frame: Days 1, 5, 26 and 27

  6. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: From signing of the informed consent form (ICF) to end of study (approximately 12 weeks)

  7. QTcI Changes Evaluated Using ECG Assessments versus Serum Concentrations of JNJ-64565111

    QTcI changes evaluated using ECG assessments versus serum concentrations of JNJ-64565111 will be quantified. QTcI is a QT interval corrected for heart rate using individual-specific correction formula and QTcI changes will be quantified using a linear or nonlinear mixed effects modeling approach.

    Time frame: Up to Day 27

07

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Feb 2019, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2018
First posted
Jul 30, 2018
StartActual
Jul 13, 2018
Primary completionActual
Feb 8, 2019
CompletionActual
Feb 28, 2019
Last update
Mar 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03606057
Responsible party
Sponsor
First posted
Jul 30, 2018
Start date
Jul 13, 2018
Primary completion
Feb 8, 2019
Completion
Feb 28, 2019
Last update
Mar 3, 2020

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efinopegdutide

Start the discussion